Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn’s Disease Intestinal Mucosa: Analysis From the CELEST Study

BACKGROUND: Janus kinase (JAK) inhibition shows promise for treatment of patients with moderate to severe Crohn’s disease. We aimed to provide mechanistic insights into the JAK1-selective inhibitor upadacitinib through a transcriptomics substudy on biopsies from patients with Crohn's disease fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilar, Daniel, Revilla, Lluís, Garrido-Trigo, Alba, Panés, Julian, Lozano, Juan J, Planell, Núria, Esteller, Miriam, Lacerda, Ana P, Guay, Heath, Butler, James, Davis, Justin Wade, Salas, Azucena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic Science Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599035/
https://www.ncbi.nlm.nih.gov/pubmed/34042156
http://dx.doi.org/10.1093/ibd/izab116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599035/
https://www.ncbi.nlm.nih.gov/pubmed/34042156
http://dx.doi.org/10.1093/ibd/izab116

Ejemplares similares